This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Applications that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics.
Deadlines:
- Letter of Intent Due Date(s): May 22, 2021 and February 09, 2022
- Application Due Date(s): June 22, 2021; March 9, 2022
RFA-DK-21-004 Expiration Date March 10, 2022
Application budgets are limited to $500,000 in direct costs per year. Budgets are expected to reflect the actual needs of the proposed project.
The maximum project period is 5 years. The scope of the proposed project should determine the project period.